Fierce Biotech

Tuberculosis cocktail stirs hopes for quick cures in patients with HIV

A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with HIV as it rolls into Phase III development.

Tue, 22 Jul 2014 14:55:29 +0000

Ziopharm, Intrexon tackle CAR-T in expanded partnership

Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.

Tue, 22 Jul 2014 13:59:36 +0000

Sage takes to the FDA fast track with its lead rare disease drug

Fresh off grossing $103.5 million in an overstuffed IPO, Cambridge, MA's Sage Therapeutics has secured the promise of a speedy FDA review for its top prospect, a treatment for a rare seizure disorder.

Tue, 22 Jul 2014 13:54:42 +0000

Biosimilars set to boom as new patent cliff on biologic superstars looms

If you look at the biosimilars market as a global whole, the sum total of revenue generated by the follow-on crowd just barely crossed into blockbuster territory in 2013, according to a new study from Allied Marketing Research. But that $1.3 billion base is expected to swell to $35 billion by 2020 as new products penetrate the market in North America, Europe and Asia.

Tue, 22 Jul 2014 13:50:59 +0000

With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia

Scientists from the Broad Institute are unveiling new genomic findings from thousands of schizophrenia patients that could lead to new molecular targets. And, thanks to the philanthropist Ted Stanley, they'll have $650 million to help find out.

Tue, 22 Jul 2014 12:33:43 +0000

AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners

AstraZeneca has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely-watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.

Tue, 22 Jul 2014 12:07:58 +0000

Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic

This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.

Tue, 22 Jul 2014 11:14:16 +0000

Bullish biotechs shoot for $400M in another big week for IPOs

After Sage Therapeutics staged a stellar debut on Friday, 6 more drug developers are expected to price IPOs this week, looking to buck some bearish trends in biotech and raise about $400 million combined.

Mon, 21 Jul 2014 15:04:17 +0000

Will AbbVie now emerge as the next megamerger target?

Now that AbbVie has hammered out its $55 billion takeover deal for Shire, analysts are looking for the next big biopharma tax inversion deal.

Mon, 21 Jul 2014 14:45:44 +0000

Cerecor raises $16M for PhII study of 'Special K' depression remedy

Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.

Mon, 21 Jul 2014 14:24:03 +0000